Loading...
•
Dec 31, 2020
Pulmonx Q4 2020 Earnings Report
Pulmonx's financial performance declined slightly in Q4 2020 due to the impact of the COVID-19 pandemic, but U.S. revenue increased.
Key Takeaways
Pulmonx Corporation reported a slight decline in worldwide revenue for Q4 2020, primarily due to the impact of the COVID-19 pandemic on international revenue. However, U.S. revenue saw an increase driven by expanded commercialization efforts. The company's gross profit and margin remained strong, but operating expenses increased due to investments in commercial and R&D functions.
Total worldwide revenue in Q4 2020 was $9.8 million, a 5% decrease compared to Q4 2019.
U.S. revenue increased by 4% to $4.9 million, driven by increased sales of the Zephyr Valve.
International revenue decreased by 12% to $5.0 million due to the continued impact of the COVID-19 pandemic.
Net loss in Q4 2020 was $9.3 million, or $0.27 per share, compared to a net loss of $4.7 million, or $2.48 per share, for the same period in 2019.
Revenue by Geographic Location
Forward Guidance
Pulmonx expects revenue for the full year 2021 to range from $46 million to $50 million, representing approximately 41% to 53% growth over the company's full year 2020 revenue. Management expects revenue for the first quarter 2021 to range from $8.0 million to $8.3 million. Pulmonx expects total operating expenses for the full year 2021 to range from $85 million to $90 million inclusive of stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...